Business AcquisitionEntrepreneurship

U.S. Immigration Policy Shifts Threaten Influx of Foreign-Born Entrepreneurs and Innovators, Report Suggests

** A new analysis highlights how America’s tradition of immigrant-driven innovation, exemplified by leaders from nations like Lebanon, faces new challenges. Sources indicate recent policy decisions on visas and research funding are creating headwinds for attracting and retaining global talent, potentially impacting economic growth and technological leadership. **CONTENT:**

A Legacy of Immigrant Entrepreneurship

Business AcquisitionDigital Media

Apple Secures U.S. Formula 1 Broadcasting Rights in Landmark Five-Year Pact

In a major shift for American motorsports coverage, Apple has inked a five-year agreement to become Formula 1’s U.S. broadcast partner starting next season. The deal follows the record-breaking success of the “F1 The Movie” collaboration and marks the end of ESPN’s tenure. Financial details of the partnership were not disclosed.

Broadcast Rights Transition

In a significant move for sports media, Apple has reportedly secured the U.S. broadcast rights for Formula One in a five-year partnership announced Friday, according to reports. The deal positions the technology giant as the primary platform for American fans beginning with the upcoming season, marking a strategic expansion into live sports broadcasting.

Energy PolicyHealthcare Technology

White House And FDA Launch Unprecedented Drug Approval Acceleration And Pricing Reform Initiative

The FDA and White House have unveiled a comprehensive policy package that dramatically accelerates drug approvals for national priority treatments while implementing international reference pricing. The initiatives include a groundbreaking voucher program, most-favored-nation pricing agreements with major pharmaceutical companies, and a new government-run drug marketplace called TrumpRx.

Regulatory Overhaul: FDA’s Ultra-Accelerated Review Program

According to reports from multiple sources, the U.S. Food and Drug Administration has launched what analysts suggest is the most significant regulatory acceleration program in its history. The Commissioner’s National Priority Voucher (CNPV) program reportedly slashes review timelines from the typical 10-12 months to just 1-2 months for drugs deemed vital to national interests.